Skip to main content

Genetic toxicology

Genetic toxicology aims to determine whether or not a given compound will induce mutations or chromosomal damage in humans. Today, new insights into the mechanisms of mutagenicity has opened up new possibilities for testing and predicting mutagenicity.

For more than 40 years, ERBC scientists conduct standard screening and regulatory assays as well as customized testing strategies to accurately assess the genotoxicity risk of any compounds (pharmaceutical ingredients, pharmaceutical impurities, human metabolites and chemicals) and help  pharmaceutical and chemical companies to take better account of ICH-and OECD guidelines They also support studies lead by other safety assessment internal teams through genetic toxicology biomarkers and mechanistic explorations.

  • Bacterial mutation assay
  • Photogenotoxicity - Ames Test
  • Gene mutation in Chinese hamster V79 cells (HPRT)
  • Mutation in L5178Y TK+/- mouse lymphoma cells (fluctuation method)
  • In vitro chromosome aberrations in Chinese hamster cells (V79 CHO) and human lymphocytes
  • In vitro micronucleus test on human lymphocytes or Chinese hamster cells (V79 CHO)
  • In vivo micronucleus test (single dose or multiple dose) in mouse and rat
  • In vivo chromosomal aberration test (single dose or multiple dose) in  rat
  • Unscheduled DNA synthesis (UDS) in primary rat hepatocytes after in vivo treatment
  • In vivo comet assay in rat
  • Combined comet assay and micronucleus test after repeated dosing in rat

Screening for lead compound identification using standard and miniaturized methods:

  • Modified 6-well bacterial mutation assay
  • In vitro micronucleus test in Chinese hamster cells (V79 CHO) or mouse lymphoma cells
  • In vitro comet assay on human leukocytes, Chinese hamster cells (V79 CHO) or mouse lymphoma cells
  • Oxidative stress: determination of 8-OH-dG (8-oxo-7,8-dihydro-2’deoxyguanosine) by LC/MS after in vivo or in vitro treatment
  • Replicative DNA Synthesis study (RDS) in primary rat hepatocytes after in vivo treatment
  • Inhibition of topoisomerase II
    • Stabilization of cleavable complex (in vitro chromosome aberration assay)
our expertise by

Therapeutic areas

Cardiology

Neurology

Pneumology

Oncology

Immuno-oncology

Allergy

Dermatology

Gastro-enterology

Analgesia/inflammation

Endocrinology

Haematology

Nephrology

A comprehensive range of preclinical models for short and long-term toxicology studies

Our animal models

John joe

Mouse

John joe

Rat

John joe

Dog

John joe

Rabbit

John joe

Marmoset

John joe

Ferret

John joe

Cynomolgus Monkeys

John joe

Guinea Pig

John joe

Cat

John joe

Hamster

John joe

MiniPig

A wide range of services that span the entire drug discovery and development continuum and can be tailored to specific research conditions

Our Services

NEED TO CREATE YOUR

UNIQUE PROJECT

Each project is managed by a study director, relying on a multi-disciplinary team of experts.